Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: A report from the gastrointestinal oncology study group of the Japan Clinical Oncology Group, JCOG 9603 trial

Japanese Journal of Clinical Oncology

Volumn 34, Issue 6, 2004, Pages 316-322

  Yamao, Takekazu ^a   Shimada, Yasuhiro ^b   Shirao, Kuniaki ^k   Ohtsu, Atsushi ^c   Ikeda, Nobumasa ^d   Hyodo, Ichinosuke ^e   Saito, Hiroshi ^f   Iwase, Hiroaki ^g   Tsuji, Yasushi ^h   Tamura, Takao ⁱ   Yamamoto, Seiichiro ^j   Yoshida, Shigeaki ^c  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d Mitoyo General Hospital   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^f YAMAGATA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^h Tonan Hospital   (Japan)

ⁱ HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^j NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^k NONE

more..

Author keywords

Ascites; Clinical trial; Gastric cancer, peritoneal dissemination; Sequential MTX 5FU chemotherapy

Indexed keywords

ACETAZOLAMIDE; ANTINEOPLASTIC AGENT; BICARBONATE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE;

ADULT; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; ARTICLE; ASCITES; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISSEMINATED CANCER; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEALTH CARE ORGANIZATION; HUMAN; HYPOKALEMIA; HYPONATREMIA; JAPAN; LEUKOPENIA; LIVER DYSFUNCTION; MALE; NAUSEA; NEUTROPENIA; ONCOLOGY; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; QUANTITATIVE ANALYSIS; RESPIRATORY FAILURE; SEPSIS; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; PERITONEUM TUMOR; STOMACH TUMOR; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; JAPAN; LEUCOVORIN; MALE; METHOTREXATE; MIDDLE AGED; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 6044256382     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh063     Document Type: Article

References (30)

1. Glimelius B, Hoffman K, Haglund U. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5: 189-90.
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodriguez MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
3. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
4. Dupont JB Jr, Lee JR, Burton GR, Cohn I Jr. Adenocarcinoma of the stomach: Review of 1497 cases. Cancer 1987;41:941-7.
5. Brenner DE. Intraperitoneal chemotherapy: A review. J Clin Oncol 1986; 4:1135-47.
6. Nakajima T. Tabular analysis of 10 000 cases of gastric cancer. Jpn J Cancer Chemother 1994;21:1813-97.
7. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy. Cancer Res 1989;49:3380-4.
8. Rustum YM, Cao S, Zhang Z. Rationale for treatment design: Biochemical modulation of 5-fluorouracil by leucovorin. Cancer J Sci Am 1998;4: 12-8.
9. Labianca R, Pessi A, Facendola G, Pirovano M, Luporini G. Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: A critical review of comparative studies. Eur J Cancer 1996 (Suppl 5);32A:S7-12.
10. Fernandes DJ, Bertino JR. 5-Fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyuridylate binding to thymidylate synthase by dihydropteroylpolyglutamates. Proc Natl Acad Sci USA 1980;77:5663-7.
11. Cadman E, Heimer R, Davis L. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drug synergism. Science 1979;205:1135-7.
12. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994;12:960-9.
13. Perez JE, Lacava JA, Dominguez ME, Rodriguez R, Barbieri MR, Ortiz EH, et al. Biochemical modulation of 5-fluorouracil by methotrexate in patients with advanced gastric carcinoma. Am J Clin Oncol 1998;21:452-7.
14. Dickinson R, Preagrave P, Levi J, Milliken S, Woods R. Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma. Cancer Chemother Pharmacol 1989;24:67-8.
15. Sasaki T, Ota K, Ibayashi J, Sakata Y, Matsuoka T, Ishikawa M, et al. Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer. Jpn J Cancer Chemother 1989;16:2545-55 (in Japanese with English abstract).
16. Konishi T, Hiraishi M, Mafune K, Miyama T, Hirata T, Mori K, et al. Therapeutic efficacy and toxicity of sequential methotrexate and 5-fluorouracil in gastric cancer. Anticancer Res 1994;14:1277-80.
17. Japanese Research Society for Gastric Cancer. Response assessment of chemotherapy for gastric carcinoma. Japanese Classification of Gastric Carcinoma, 1st Engl ed. Tokyo: Kanehara 1995; 90-104.
18. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993;23:250-7.
19. Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA, Krook JE, et al. Controlled evaluation of three drug combination regimens vs. fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol 1994;12:412-6.
20. Kim NK, Park YS, Heo DS, Suh G, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin vs. 5-fluorouracil, doxorubicin and mitomycin C vs. 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-8.
21. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG 9205). J Clin Oncol 2003;21:54-9.
22. Vanhoefer U, Rougier P, Wilke M, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil and doxorubicin vs. etoposide, leucovorin and 5-fluorouracil vs. infusional 5-fluorouracil and cisplatin in advanced gastric cancer; a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-57.
23. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin and 5-fluorouracil vs. 5-fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7.
24. Ajani JA. Standard chemotherapy for gastric carcinoma: Is it a myth? J Clin Oncol 2000;18:4001-3.
25. Dupont JB, Lee JR. Burton GR, Cohn I Jr. Adenocarcinoma of the stomach: review of 1,497 cases. Cancer 1978;41:941-7.
26. Dedric RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1-11.
27. Reichman B, Markman M, Hakes T, Kemeny N, Kelsen D, Hoskins W, et al. Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer. J Clin Oncol 1988;6:158-62.
28. Markman M, Reichman B, Hakes T, Lewis JL Jr, Jones W, Rubin S, et al. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol 1992;10:1479-84.
29. Chabner BA, Stoller RG, Hande K, Jacobs S, Young RC. Methotrexate disposition in humans: Drug Metab Rev 1978;8:107-17.
30. Konishi T, Miyama T, Sakamoto S, Hirata T, Mafune K, Hiraishi M, et al. Activity of thymidylate synthetase and thymidine kinase in gastric cancer. Surg Oncol 1992;1:215-21.